Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.
G. Shapiro
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
P. LoRusso
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
E. L. Kwak
No relevant relationships to disclose
J. M. Cleary
No relevant relationships to disclose
L. Musib
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
C. Jones
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
A. de Crespigny
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
M. Belvin
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
M. McKenzie
Employment or Leadership Position - Genentech
M. R. Gates
Employment or Leadership Position - Genentech
I. T. Chan
Employment or Leadership Position - Genentech
J. C. Bendell
No relevant relationships to disclose